Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN): Price and Financial Metrics


Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN): $133.61

-1.18 (-0.88%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BHVN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

BHVN POWR Grades


  • Sentiment is the dimension where BHVN ranks best; there it ranks ahead of 56.43% of US stocks.
  • BHVN's strongest trending metric is Momentum; it's been moving down over the last 51 weeks.
  • BHVN ranks lowest in Quality; there it ranks in the 5th percentile.

BHVN Stock Summary

  • Biohaven Pharmaceutical Holding Co Ltd's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 5.03% of US listed stocks.
  • BHVN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 3.8% of US stocks.
  • Revenue growth over the past 12 months for Biohaven Pharmaceutical Holding Co Ltd comes in at 1,647.02%, a number that bests 99.34% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Biohaven Pharmaceutical Holding Co Ltd, a group of peers worth examining would be ITCI, LQDA, OVID, ADXS, and GENE.
  • Visit BHVN's SEC page to see the company's official filings. To visit the company's web site, go to www.biohavenpharma.com.

BHVN Valuation Summary

  • BHVN's EV/EBIT ratio is -10.5; this is 135.84% lower than that of the median Healthcare stock.
  • Over the past 53 months, BHVN's price/sales ratio has gone NA NA.
  • BHVN's price/sales ratio has moved NA NA over the prior 53 months.

Below are key valuation metrics over time for BHVN.

Stock Date P/S P/B P/E EV/EBIT
BHVN 2021-08-31 45.3 -18.9 -9.7 -10.5
BHVN 2021-08-30 45.5 -19.0 -9.7 -10.5
BHVN 2021-08-27 44.9 -18.8 -9.6 -10.4
BHVN 2021-08-26 43.3 -18.1 -9.2 -10.0
BHVN 2021-08-25 44.2 -18.5 -9.4 -10.2
BHVN 2021-08-24 43.3 -18.1 -9.2 -10.0

BHVN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BHVN has a Quality Grade of D, ranking ahead of 5.6% of graded US stocks.
  • BHVN's asset turnover comes in at 0.228 -- ranking 186th of 681 Pharmaceutical Products stocks.
  • ITCI, OCX, and LFVN are the stocks whose asset turnover ratios are most correlated with BHVN.

The table below shows BHVN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.228 0.766 -1.928
2021-03-31 0.147 0.717 -2.515
2020-12-31 0.105 0.722 -3.394
2020-09-30 0.055 0.729 -8.301
2020-06-30 0.025 0.679 14.638
2020-03-31 0.003 0.632 18.015

BHVN Stock Price Chart Interactive Chart >

Price chart for BHVN

BHVN Price/Volume Stats

Current price $133.61 52-week high $151.51
Prev. close $134.79 52-week low $62.57
Day low $132.87 Volume 369,600
Day high $136.00 Avg. volume 596,177
50-day MA $130.72 Dividend yield N/A
200-day MA $98.27 Market Cap 8.74B

Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN) Company Bio


Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. The company was founded in 2013 and is based in New Haven, Connecticut.


BHVN Latest News Stream


Event/Time News Detail
Loading, please wait...

BHVN Latest Social Stream


Loading social stream, please wait...

View Full BHVN Social Stream

Latest BHVN News From Around the Web

Below are the latest news stories about Biohaven Pharmaceutical Holding Co Ltd that investors may wish to consider to help them evaluate BHVN as an investment opportunity.

Biohaven (BHVN) Q3 Nurtec Preliminary Sales Top Expectations

Biohaven's (BHVN) sole marketable drug, Nurtec ODT reports preliminary sales for the third quarter, which beat expectations.

Yahoo | October 6, 2021

Biohaven Stock, With A Kardashian-Backed Drug, Hit A Record And Then Sank

Biohaven crushed Wall Street's third-quarter forecasts for migraine tablet Nurtec ODT. But BHVN stock gave back its early gains.

Yahoo | October 5, 2021

Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the third quarter of 2021.

Yahoo | October 5, 2021

Biotech Stock Roundup: XLRN Up on Takeover Rumor, NVAX, BIIB Offer Updates & More

Regulatory and pipeline updates from bigwigs like Biogen (BIIB) and Novavax (NVAX) have been some of the key highlights in the biotech sector during the past week.

Yahoo | September 29, 2021

Biohaven (BHVN) Phase III Multiple System Atrophy Study Fails

Biohaven's (BHVN) myeloperoxidase enzyme inhibitor, verdiperstat fails to statistically differentiate from placebo in improving disease progression in patients with multiple system atrophy in a late-stage study.

Yahoo | September 28, 2021

Read More 'BHVN' Stories Here

BHVN Price Returns

1-mo -1.03%
3-mo 5.12%
6-mo 77.96%
1-year 71.45%
3-year 281.96%
5-year N/A
YTD 55.89%
2020 57.44%
2019 47.21%
2018 37.06%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9842 seconds.